Corvus Q4 net loss $12.3M; soquelitinib atopic dermatitis Ph1 75% EASI75; raises $189M

Corvus Pharmaceuticals, Inc.

Net loss for Q4 2025 was $12.3M; R&D expenses $9.9M (up from $6.0M in Q4 2024).
Cash $56.8M at Dec 31, 2025; $189.4M net from Jan 2026 offering extends runway into Q2 2028.
Cohort 4 atopic dermatitis: 75% soquelitinib patients achieved EASI 75 vs 20% placebo; 33% IGA 0/1 vs 0%.
Initiated Phase 2 atopic dermatitis trial in Q1 2026; ~200 patients, four dose arms, 12-week treatment.
Phase 3 PTCL registrational trial enrolling; soquelitinib granted Fast Track and Orphan Drug Designation.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Corvus Pharmaceuticals, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.

Period: the fourth quarter and full year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 12, 2026, Corvus Pharmaceuticals, Inc. issued a press release regarding, among other matters, its financial results for the fourth quarter and full year ended December 31, 2025 and its financial position as of December 31, 2025, and provided a business update.

View on SEC.gov

Browse all earnings releases →

Corvus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-26-001526

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.